Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors

Despite therapeutic improvements, resistance to palbociclib is a growing clinical challenge which is poorly understood. This study was conducted in order to understand the molecular mechanisms of resistance to palbociclib, and to identify biomarkers to predict who will take advantage from cyclin-dep...

Full description

Bibliographic Details
Main Authors: Lucrezia Raimondi, Filippo Maria Raimondi, Marta Pietranera, Arianna Di Rocco, Laura Di Benedetto, Evelina Miele, Rachele Lazzeroni, Giuseppe Cimino, Gian Paolo Spinelli
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
metastatic breast cancer
targeted therapy
KRAS
CDK4/6 inhibitors
liquid biopsy
ddPCR
Online Access:https://www.mdpi.com/2072-6694/13/8/1928

Internet

https://www.mdpi.com/2072-6694/13/8/1928

Similar Items